Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 151 articles:
HTML format
Text format



Single Articles


    October 2018
  1. BASAL E, Zalewski N, Kryzer TJ, Hinson SR, et al
    Paraneoplastic neuronal intermediate filament autoimmunity.
    Neurology. 2018 Oct 3. pii: WNL.0000000000006435.
    PubMed     Text format     Abstract available


  2. ALGAEED M, Mukharesh L, Heinzelmann M, Kaminski HJ, et al
    Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2018;91:e1365-e1367.
    PubMed     Text format    


    September 2018
  3. CAVALLA P, Gilmore W
    Pregnancy in multiple sclerosis: Data from an administrative claims database.
    Neurology. 2018 Sep 28. pii: WNL.0000000000006371.
    PubMed     Text format    



  4. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018;91:538.
    PubMed     Text format    


    August 2018
  5. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed     Text format    


  6. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006246.
    PubMed     Text format     Abstract available


  7. BROWNLEE WJ, Miszkiel KA, Tur C, Barkhof F, et al
    Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.
    Neurology. 2018 Aug 17. pii: WNL.0000000000006207.
    PubMed     Text format     Abstract available


    July 2018
  8. BEDARF JR, Nelles M, Reimann J, Paus S, et al
    Teaching Video NeuroImages: Propriospinal myoclonus as a sequela of Guillain-Barre syndrome.
    Neurology. 2018;91:e297-e299.
    PubMed     Text format    


  9. MARQUES-MATOS C, Melo C, Sampaio M, Rodrigues E, et al
    Child Neurology: Treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity.
    Neurology. 2018;91:98-101.
    PubMed     Text format    


    June 2018
  10. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
    Neurology. 2018 Jun 27. pii: WNL.0000000000005853.
    PubMed     Text format     Abstract available


  11. PRADOS F, Barkhof F
    Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?
    Neurology. 2018 Jun 27. pii: WNL.0000000000005873.
    PubMed     Text format    


  12. HAGENS MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, et al
    Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
    Neurology. 2018 Jun 20. pii: WNL.0000000000005825.
    PubMed     Text format     Abstract available


  13. VITT JR, Kreple C, Mahmood N, Dickerson E, et al
    Autoimmune pancerebellitis associated with pembrolizumab therapy.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005781.
    PubMed     Text format    


  14. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Text format     Abstract available


    May 2018
  15. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Text format     Abstract available


  16. KIM DD, Ho C, King R, Morrow SA, et al
    Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.
    Neurology. 2018;90:e1929-e1932.
    PubMed     Text format    


  17. LIEWLUCK T
    Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  18. BUDHRAM A
    Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  19. KARAM C, Galetta S
    Editors' note: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:989.
    PubMed     Text format    


  20. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Text format     Abstract available


  21. DE LORENZO R, Pinal-Fernandez I, Huang W, Albayda J, et al
    Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    Neurology. 2018 May 4. pii: WNL.0000000000005638.
    PubMed     Text format     Abstract available


  22. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed     Text format    


  23. LOPEZ CHIRIBOGA AS, Matsumoto J, Sorenson E, Klein CJ, et al
    Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity.
    Neurology. 2018;90:e1636-e1637.
    PubMed     Text format    


    April 2018
  24. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Text format     Abstract available


  25. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Text format     Abstract available


  26. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Text format     Abstract available


  27. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Text format     Abstract available


  28. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Text format     Abstract available


  29. HEWETT K, Sanders DB, Grove RA, Broderick CL, et al
    Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
    Neurology. 2018;90:e1425-e1434.
    PubMed     Text format     Abstract available


  30. PEDROSO JL, Dutra LA, Espay AJ, Hoftberger R, et al
    Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
    Neurology. 2018;90:746-747.
    PubMed     Text format    


  31. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed     Text format    


    March 2018
  32. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed     Text format    


  33. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed     Text format    


  34. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Text format     Abstract available


  35. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Text format     Abstract available


  36. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed     Text format    


  37. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Text format     Abstract available


  38. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed     Text format    


  39. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Text format     Abstract available


    February 2018
  40. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Text format     Abstract available


  41. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Text format     Abstract available


  42. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Text format     Abstract available


  43. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Text format     Abstract available


    January 2018
  44. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed     Text format    


  45. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Text format     Abstract available


  46. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Text format     Abstract available


  47. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Text format     Abstract available


  48. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Text format     Abstract available


  49. ALLENBACH Y, Arouche-Delaperche L, Preusse C, Radbruch H, et al
    Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement.
    Neurology. 2018 Jan 12. pii: WNL.0000000000004923.
    PubMed     Text format     Abstract available


  50. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Text format     Abstract available


    December 2017
  51. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Text format     Abstract available


  52. DUBEY D, Lennon VA, Gadoth A, Pittock SJ, et al
    Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
    Neurology. 2017 Dec 8. pii: WNL.0000000000004803.
    PubMed     Text format     Abstract available


  53. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed     Text format    


  54. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Text format     Abstract available


  55. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed     Text format    


    November 2017
  56. BURNOR E, Yang L, Zhou H, Patterson KR, et al
    Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
    Neurology. 2017 Nov 29. pii: WNL.0000000000004773.
    PubMed     Text format     Abstract available


  57. KLAWITER EC, Bove R, Elsone L, Alvarez E, et al
    High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
    Neurology. 2017;89:2238-2244.
    PubMed     Text format     Abstract available


  58. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Text format     Abstract available


  59. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed     Text format    


  60. DHAWAN PS, Dyck PJB, Tracy JA, Naddaf E, et al
    Systemic vasculitis with dermatomyositis, hearing loss, neuropathy, and multiorgan dysfunction.
    Neurology. 2017;89:2119-2120.
    PubMed     Text format    


  61. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Text format     Abstract available


  62. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Text format     Abstract available


  63. HOUZEN H, Kondo K, Niino M, Horiuchi K, et al
    Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    Neurology. 2017;89:1995-2001.
    PubMed     Text format     Abstract available


  64. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Text format     Abstract available


  65. BARNETT C, Bril V, Kapral M, Kulkarni AV, et al
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004676.
    PubMed     Text format     Abstract available


    October 2017
  66. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Text format     Abstract available


  67. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed     Text format    


  68. MATHIS S, Magy L, Le Masson G, Vallat JM, et al
    Did Jules Dejerine describe AMAN at the end of the 19th century?
    Neurology. 2017;89:1749-1753.
    PubMed     Text format     Abstract available


  69. KARGIOTIS O, Safouris A, Petrou VN, Magoufis G, et al
    Teaching NeuroImages: Giant cell arteritis presenting with acute ischemic strokes due to diffuse intracranial stenoses.
    Neurology. 2017;89:e190-e191.
    PubMed     Text format    


  70. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed     Text format    


  71. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Text format     Abstract available


    September 2017
  72. LIEWLUCK T
    Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004610.
    PubMed     Text format    


  73. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    


  74. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    


  75. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    


  76. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    


  77. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  78. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Text format     Abstract available


  79. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed     Text format    


  80. LOPEZ-CHIRIBOGA AS, Clardy SL
    Emerging Subspecialties in Neurology: Autoimmune neurology.
    Neurology. 2017;89:e129-e133.
    PubMed     Text format    


  81. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed     Text format    


  82. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed     Text format    


  83. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available


  84. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available


  85. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Text format     Abstract available


    August 2017
  86. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Text format     Abstract available


  87. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Text format     Abstract available


  88. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Text format     Abstract available


  89. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed     Text format    


  90. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Text format     Abstract available


  91. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed     Text format    


  92. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Text format     Abstract available


  93. SUZUKI S, Ishikawa N, Konoeda F, Seki N, et al
    Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004359.
    PubMed     Text format     Abstract available


  94. BEECHER G, Anderson D, Siddiqi ZA
    Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004365.
    PubMed     Text format     Abstract available



  95. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed     Text format    


  96. HEHIR MK, Hobson-Webb LD, Benatar M, Barnett C, et al
    Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Neurology. 2017 Aug 11. pii: 10.1212/WNL.0000000000004341.
    PubMed     Text format     Abstract available


    July 2017
  97. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed     Text format    


  98. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed     Text format    


  99. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed     Text format    


  100. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Text format     Abstract available


  101. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Text format     Abstract available


  102. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Text format     Abstract available



  103. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  104. URUHA A, Suzuki S, Nishino I
    Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  105. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Text format     Abstract available


    June 2017
  106. LEWIS EJH, Perkins BA, Lovblom LE, Bazinet RP, et al
    Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
    Neurology. 2017;88:2294-2301.
    PubMed     Text format     Abstract available


  107. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Text format     Abstract available


  108. BRENNA G, Antozzi C, Montomoli C, Baggi F, et al
    A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004082.
    PubMed     Text format     Abstract available


    May 2017
  109. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Text format     Abstract available


  110. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  111. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  112. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  113. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  114. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed     Text format    


  115. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed     Text format    


  116. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


  117. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Text format     Abstract available


  118. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Text format     Abstract available


    April 2017
  119. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  120. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


  121. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Text format     Abstract available


  122. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Text format     Abstract available


    March 2017
  123. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  124. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


    February 2017
  125. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  126. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  127. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  128. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed     Text format    


  129. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  130. WYNN DP, Donigan JM, Tkach A
    Clinical Reasoning: A 74-year-old woman with bilateral foot pain and a palmar rash.
    Neurology. 2017;88:e44-e50.
    PubMed     Text format    


  131. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  132. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  133. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Text format     Abstract available


  134. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


    December 2016
  135. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


  136. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Text format     Abstract available


    November 2016
  137. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    


    October 2016
  138. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


    September 2016
  139. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  140. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    July 2016
  141. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed     Text format    


  142. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Text format     Abstract available


  143. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed     Text format    


    May 2016
  144. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Text format     Abstract available


  145. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Text format     Abstract available


  146. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Text format     Abstract available


  147. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed     Text format    


  148. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Text format     Abstract available


  149. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Text format     Abstract available


    April 2016
  150. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available


    March 2016
  151. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: